Table 2. Predictive effects of the E2F score in resected lung adenocarcinoma patients.
| Overall survival | No ACT | With ACT | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Median survival | 5-year Survival rate (%) |
N | Median survival | 5-year Survival rate (%) |
Log-rank test p-value |
HR** (95% CI) ACT vs No ACT | Int-P*** | |||
| Individual cohorts: JBR10.AD[22]: Fresh Frozen | |||||||||||
| Low E2F group (N=48) | 21 | NR* | 71 | 27 | 72.4 | 66 | 0.154 | 1.92 (0.77, 4.77) | 0.016 | ||
| High E2F group (N=23) | 11 | 36.4 | 22 | 12 | 73.1 | 75 | 0.043 | 0.31 (0.1, 1.01) | |||
| NATCH[7]: FFPE | |||||||||||
| Low E2F group (N=23) | 13 | 81.5 | 69 | 10 | NR | 51 | 0.631 | 1.4 (0.35, 5.64) | 0.407 | ||
| High E2F group (N=51) | 27 | 25.1 | 20 | 24 | 65.6 | 52 | 0.162 | 0.61 (0.3, 1.23) | |||
|
Combined cohorts (JBR10.AD and NATCH): All stages | |||||||||||
| Low E2F group (N=71) | 34 | NR | 70 | 37 | 72.4 | 63 | 0.195 | 1.62 (0.78, 3.36) | 0.016 | ||
| High E2F group (N=74) | 38 | 25.1 | 20 | 36 | 69.7 | 60 | 0.023 | 0.51 (0.28, 0.92) | |||
| Stage I | |||||||||||
| Low E2F group (N=46) | 24 | NR | 83 | 22 | NR | 77 | 0.202 | 2.05 (0.67, 6.28) | 0.184 | ||
| High E2F group (N=34) | 18 | 48.5 | 31 | 16 | 73.1 | 61 | 0.526 | 0.75 (0.30, 1.85) | |||
| Stage II | |||||||||||
| Low E2F group (N=20) | 7 | 73.2 | 57 | 13 | 57.8 | 41 | 0.466 | 1.55 (0.47, 5.13) | 0.015 | ||
| High E2F group (N=22) | 11 | 18 | 18 | 11 | NR | 81 | 0.012 | 0.21 (0.06, 0.80) | |||
| Stage III/IV | |||||||||||
| Low E2F group (N=5) | 3 | 22.8 | 0 | 2 | 22.5 | ≤50 | 0.455 | 0.43 (0.04, 4.20) | 0.74 | ||
| High E2F group (N=18) | 9 | 17.6 | 0 | 9 | 20.3 | 33 | 0.302 | 0.57 (0.20, 1.65) | |||
NR*: median survival time not reached within the study
HR**: hazard ratio
Int-P***: P value of interaction effect
Significant P values are in bold text